Dupilumab: Newer off-label dermatological indications and clinical implications

Abstract

Dupilumab, initially approved for atopic dermatitis, has demonstrated promising efficacy in various off-label dermatological conditions. This part 2 review explores the growing evidence supporting its use in conditions such as lichen planus, Lichen planus pemphigoids, Kimura’s disease, chronic pruritus, and many others. The mechanisms of action, clinical outcomes, and safety profiles associated with dupilumab in these off-label indications are also discussed. As research continues to evolve, dupilumab’s potential as a versatile therapeutic option for dermatological disorders becomes increasingly apparent.